Work

Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.7511

Authors: Loretta J. Nastoupil, Matthew Alexander Lunning, Julie Vose, Marshall T. Schreeder, Tanya Siddiqi, Christopher Flowers, Jonathon Brett Cohen, Jan Andreas Burger, William G. Wierda, Susan Mary O'Brien, Peter Sportelli, Hari P. Miskin, Michelle A Purdom, Michael S. Weiss, Nathan Hale Fowler

Institutions: The University of Texas MD Anderson Cancer Center, University of Nebraska Medical Center, Clearview Cancer Institute, City Of Hope National Medical Center, Winship Cancer Institute, University of California, Irvine, TG Therapeutics, Inc. (United States)

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2777962143

Cites:

Cited by: 4

Related to: 10